tiprankstipranks
Trending News
More News >
Pharming Group (PHAR)
NASDAQ:PHAR
US Market
Advertisement

Pharming Group (PHAR) Stock Forecast & Price Target

Compare
146 Followers
See the Price Targets and Ratings of:

PHAR Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Pharming
Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PHAR Stock 12 Month Forecast

Average Price Target

$39.00
▲(220.99% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Pharming Group in the last 3 months. The average price target is $39.00 with a high forecast of $41.00 and a low forecast of $37.00. The average price target represents a 220.99% change from the last price of $12.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","15":"$15","24":"$24","33":"$33","42":"$42"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15,24,33,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.96,13.270769230769233,15.581538461538463,17.892307692307693,20.203076923076924,22.513846153846156,24.824615384615385,27.135384615384616,29.446153846153848,31.75692307692308,34.06769230769231,36.378461538461536,38.689230769230775,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.96,13.116923076923078,15.273846153846154,17.43076923076923,19.587692307692308,21.744615384615386,23.90153846153846,26.058461538461536,28.215384615384615,30.372307692307693,32.529230769230765,34.68615384615384,36.84307692307692,{"y":39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.96,12.963076923076924,14.966153846153848,16.96923076923077,18.972307692307695,20.975384615384616,22.978461538461538,24.981538461538463,26.984615384615385,28.987692307692306,30.99076923076923,32.99384615384615,34.996923076923075,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.45,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.63,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$41.00Average Price Target$39.00Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PHAR
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Buy
11.11%
Upside
Upgraded
08/05/25
Pharming Group's overall score is driven primarily by its strong earnings call and positive technical momentum. While financial performance shows growth potential, challenges in profitability and valuation are notable risks. The absence of corporate events and a negative P/E ratio limit upside but the positive earnings outlook and technical indicators suggest potential for future gains.
Oppenheimer Analyst forecast on PHAR
Jeff JonesOppenheimer
Oppenheimer
$41
Buy
237.45%
Upside
Reiterated
08/01/25
Pharming price target raised to $41 from $40 at OppenheimerPharming price target raised to $41 from $40 at Oppenheimer
H.C. Wainwright Analyst forecast on PHAR
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$37
Buy
204.53%
Upside
Reiterated
08/01/25
Pharming Group's Strong Financial Performance and Strategic Developments Justify Buy RatingValuation and risks to achieving it. We reiterate our Buy rating and $37 price target on the U.S.-traded ADRs of Pharming. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Ruconest contributes 48% to our valuation and Joenja contributes 52%. We look to add KL1333 to our valuation in the future, representing potential significant upside, whereas now we believe the company is undervalued on the Ruconest and Joenja opportunities alone.
Jefferies
$14
Buy
15.23%
Upside
Initiated
12/09/24
Pharming initiated with a Buy at JefferiesPharming initiated with a Buy at Jefferies
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PHAR
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Buy
11.11%
Upside
Upgraded
08/05/25
Pharming Group's overall score is driven primarily by its strong earnings call and positive technical momentum. While financial performance shows growth potential, challenges in profitability and valuation are notable risks. The absence of corporate events and a negative P/E ratio limit upside but the positive earnings outlook and technical indicators suggest potential for future gains.
Oppenheimer Analyst forecast on PHAR
Jeff JonesOppenheimer
Oppenheimer
$41
Buy
237.45%
Upside
Reiterated
08/01/25
Pharming price target raised to $41 from $40 at OppenheimerPharming price target raised to $41 from $40 at Oppenheimer
H.C. Wainwright Analyst forecast on PHAR
Joseph PantginisH.C. Wainwright
H.C. Wainwright
$37
Buy
204.53%
Upside
Reiterated
08/01/25
Pharming Group's Strong Financial Performance and Strategic Developments Justify Buy RatingValuation and risks to achieving it. We reiterate our Buy rating and $37 price target on the U.S.-traded ADRs of Pharming. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Ruconest contributes 48% to our valuation and Joenja contributes 52%. We look to add KL1333 to our valuation in the future, representing potential significant upside, whereas now we believe the company is undervalued on the Ruconest and Joenja opportunities alone.
Jefferies
$14
Buy
15.23%
Upside
Initiated
12/09/24
Pharming initiated with a Buy at JefferiesPharming initiated with a Buy at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharming Group

1 Month
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
+2.46%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +2.46% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+5.40%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +5.40% per trade.
1 Year
Joseph PantginisH.C. Wainwright
Not Ranked
Success Rate
10/13 ratings generated profit
77%
Average Return
+19.96%
reiterated a buy rating 8 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +19.96% per trade.
2 Years
xxx
Success Rate
12/13 ratings generated profit
92%
Average Return
+30.24%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +30.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHAR Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
5
3
2
3
Buy
0
0
0
0
1
Hold
5
5
6
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
9
9
11
In the current month, PHAR has received 4 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. PHAR average Analyst price target in the past 3 months is 39.00.
Each month's total comprises the sum of three months' worth of ratings.

PHAR Financial Forecast

PHAR Earnings Forecast

Next quarter’s earnings estimate for PHAR is <$0.01 with a range of >-$0.01 to $0.01. The previous quarter’s EPS was $0.06. PHAR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year PHAR has Outperformed its overall industry.
Next quarter’s earnings estimate for PHAR is <$0.01 with a range of >-$0.01 to $0.01. The previous quarter’s EPS was $0.06. PHAR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year PHAR has Outperformed its overall industry.

PHAR Sales Forecast

Next quarter’s sales forecast for PHAR is $98.22M with a range of $93.43M to $103.01M. The previous quarter’s sales results were $94.37M. PHAR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year PHAR has Outperformed its overall industry.
Next quarter’s sales forecast for PHAR is $98.22M with a range of $93.43M to $103.01M. The previous quarter’s sales results were $94.37M. PHAR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year PHAR has Outperformed its overall industry.

PHAR Stock Forecast FAQ

What is PHAR’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharming Group’s 12-month average price target is 39.00.
    What is PHAR’s upside potential, based on the analysts’ average price target?
    Pharming Group has 220.99% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PHAR a Buy, Sell or Hold?
          Pharming Group has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Pharming Group’s price target?
            The average price target for Pharming Group is 39.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $41.00 ,the lowest forecast is $37.00. The average price target represents 220.99% Increase from the current price of $12.15.
              What do analysts say about Pharming Group?
              Pharming Group’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of PHAR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis